The partnership between these companies stems from a late 2024 licensing agreement in which Corxel obtained worldwide rights to CX11, excluding China, from Vincentage.
The merger has already cleared several regulatory hurdles, having secured approval from the Competition Commission of India (CCI) and received ‘No Objection’ letters from the Stock Exchanges.
The grant will enable Qure.ai to develop a comprehensive open-source multi-modal database designed to accelerate future prevention and identification innovations.
The approval specifically targets patients who have already undergone one prior trastuzumab-based treatment regimen.
BMS will pay up to USD850 million, structured as USD50 million in upfront and near-term payments combined with USD800 million in regulatory, development, and milestone-based payouts.
The newly developed syringe has been specifically engineered to work seamlessly with Ypsomed’s YpsoMate 5.5 autoinjector platform.
The acquisition adds two key products to BioStem’s portfolio: Neox and Clarix, both cryopreserved amniotic membrane allografts.
The device works by carefully opening the obstructed prostate, providing relief from lower urinary tract symptoms that significantly impact patients’ daily lives.
Pfizer will assume complete responsibility for developing and bringing to market any vaccine products that utilize Matrix-M technology.
Doctors now use these highly realistic training tools to master complex surgical procedures, refine ultrasound diagnostic techniques, and verify the accuracy of CT and MRI imaging equipment.